Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Trial Profile

Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
    • 18 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top